A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancerElgene Lim,Erika Hamilton,Carlo Palmieri,Hendrik-Tobias Arkenau, Sue Brook, Geoff Fisher, Andrew MazurCANCER RESEARCH（2023）引用 0|浏览15暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
